Bank of America Initiates Coverage on Ultragenyx Pharmaceutical Inc to Buy

Bank of America Initiates Coverage on Ultragenyx Pharmaceutical Inc(NASDAQ:RARE). The shares have been rated Buy. The rating by Bank of America was issued on Jun 28, 2016.

In a different note, On Jun 8, 2016, JMP Securities said it Maintains its rating on Ultragenyx Pharmaceutical Inc. In the research note, the firm Raises the price-target to $80.00 per share. The shares have been rated ‘Market Outperform’ by the firm.

Ultragenyx Pharmaceutical Inc (RARE) made into the market gainers list on Fridays trading session with the shares advancing 5.72% or 2.8 points. Due to strong positive momentum, the stock ended at $51.71, which is also near the day’s high of $52.2. The stock began the session at $49.19 and the volume stood at 5,47,514 shares. The 52-week high of the shares is $137.05 and the 52 week low is $46.52. The company has a current market capitalization of $2,018 M and it has 3,90,20,576 shares in outstanding.

Ultragenyx Pharmaceutical Inc(RARE) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-1.35. Analysts had estimated an EPS of $-1.29.

Several Insider Transactions has been reported to the SEC. On Jun 21, 2016, Sunil Agarwal (Chief Medical Officer) sold 650 shares at $54.16 per share price.Also, On May 18, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $60.74 per share price.On Dec 18, 2015, Theodore Alan Huizenga (Controller and PAO) sold 1,500 shares at $110.55 per share price, according to the Form-4 filing with the securities and exchange commission.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *